Company Overview and News
Suresh P Iyengar Thanks to the ‘Mutual Funds Sahi Hain’ campaign, the industry seems to have hit the right growth trajectory even as uncertainty looms large on the growth prospects of the economy and corporate earnings.
HDFC Mutual Fund will introduce HDFC Flex systematic investment plan for investments under the growth option plan of open-ended equity and balanced funds, with effect from April 3, the mutual fund house said in an addendum.
IDFC Asset Management Company is up for sale, and may soon be acquired by another large mutual fund player or a company as the AMC’s parent, IDFC is looking to exit the AMC business.
Our Bureau Housing Development Finance Corporation, a mortgage lending firm, has decided to offload a little over 4 per cent of its holding in its subsidiary HDFC Asset Management Company through an initial public offering.
Fixed Maturity Plans or FMPs are back in the game in a big way with new fund offers from 10 mutual fund houses already on, and many more set for launch in the days to come.
HDFC Mutual Fund held a 4.37 percent stake in the beleaguered Punjab National Bank as at the end of the October-December quarter. The bank has been hit by fraudulent transactions of over Rs 11,000 crore.
3:30 pm Market at Close: After trading rangebound for a larger part of the day, market has ended the day on a flat note. The Sensex was up 15.75 points at 36155.73, while the Nifty was up 2.30 points at 11086.00. The market breadth favoured the declines as 1005 shares advanced, against a decline of 1895 shares, while 240 shares were unchanged.
HDFC Mutual Fund will revise the dividend record date under the monthly option of HDFC Arbitrage Fund - Wholesale Plan with effect from February 1, the fund house said in a newspaper notice.
11h - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
11h - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...